Cameron Santoro

A Chinese phase 3 trial found biosimilar QL1207 to be as effective and safe as reference aflibercept (Eylea) for the treatment of neovascular age-related macular degeneration (nAMD).

Here are the top 5 articles for the week of February 26, 2024.

Ha Kung Wong, JD, examines proposed patent law changes that could significantly impact the biosimilars sector, including limitations on asserted patents, elimination of interchangeability requirements, and heightened oversight of pharmacy benefit managers.

Here are the top 5 biosimilar articles for the week of February 19, 2024.

A large Chinese study found that HanliKang (HLX01), a biosimilar rituximab, had similar overall survival and progression-free survival rates to the reference product (Rituxan) in patients with diffuse large B-cell lymphoma (DLBCL).

Here are the top 5 biosimilar articles for the week of February 12, 2024.

Similar efficacy, safety, pharmacokinetics, and immunogenicity were found when comparing Stelara, originator ustekinumab, and CT-P43, an ustekinumab biosimilar candidate, in patients with moderate to severe plaque psoriasis.

In an interview with Ha Kung Wong, JD, he addresses the patent legal system biosimilars are required to undergo and how this helps resolve patent disputes early in the development process.

Here are the top 5 biosimilar articles for the week of February 5, 2024.

Etanercept biosimilar SB4 is just as effective as the originator drug (Enbrel) in treating Australian patients with rheumatoid arthritis (RA), leading to significant cost savings.

Here are the top 5 biosimilar articles for the week of January 29, 2024.

A study found SB15, an aflibercept biosimilar, is just as effective as its reference drug Eylea, the current standard treatment for neovascular age-related macular degeneration (nAMD), a condition that causes vision loss.

A 10-year analysis in Poland found that the introduction of biosimilar drugs significantly increased access to biologic therapies and Janus kinase (JAK) inhibitors for patients with rheumatic musculoskeletal diseases (RMDs), while also reducing treatment costs.

Here are the top 5 biosimilar articles for the week of January 22, 2024.

A combined analysis of 3 studies found that the drug MB02 is comparable to reference bevacizumab (Avastin) in terms of its pharmacokinetics, safety, and immunogenicity.

Biosimilar uptake was greater in Medicare Advantage plans when compared with traditional Medicare plans.

Here are the top 5 biosimilar articles for the week of January 15, 2024.

A French study found that rituximab biosimilars, Rixathon and Truxima, were as effective and safe as the reference drug (Rituxan) in treating immune thrombocytopenia.

Here are the top 5 biosimilar articles for the week of January 8, 2024.

A recent study found that the COVID-19 pandemic had little impact on the knowledge and attitudes of German and Swiss pharmacists regarding biologics and biosimilars between 2020 and 2022.

Here are the top 5 biosimilar articles for the week of January 1, 2024.

Adults with inflammatory diseases maintained disease control when transitioning from originator adalimumab (Humira) to biosimilar SB5 in a pan-European study.

Here are the top 5 biosimilar articles for 2023.

Here are the top 5 biosimilar articles for the week of December 18th, 2023.

Comprehensive assay research concluded similar structures, functions, and stability between reference adalimumab (Humira) and adalimumab-aqvh.

Here are the top 5 biosimilar articles for the week of December 11, 2023.

A national study on patients with rheumatoid arthritis (RA) compares the disease activity and drug survival rate between an etanercept biosimilar and the originator (Enbrel).

Here are the top 5 biosimilar articles for the week of December 4, 2023.

Patients with inflammatory bowel disease (IBD) receive additional evidence on the safety and efficacy of adalimumab biosimilar GP2017 treatment.

Here are the top 5 biosimilar articles for the week of November 27, 2023.